Bioxyne (ASX:BXN) signed an exclusive AU$7 million manufacturing and supply agreement with its existing customer, NectarTek Australia, according to a Thursday Australian bourse filing.
Its unit Breathe Life Sciences was named as the exclusive manufacturer of all NectarTek products for distribution in Australia, the UK, and Germany.
The agreement includes volume commitments which are expected to generate at least AU$7 million in revenue for Bioxyne in the fiscal year 2026.
The contract includes minimum order volumes of AU$3.6 million of pastilles, AU$2.5 million of packed flower products, AU$500,000 of vapes, and AU$500,000 of oral mucosal oils and other products.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.